New drug BC006 aims to slow lung scarring in IPF patients

NCT ID NCT07447102

Recruiting now Disease control Sponsor: Dragonboat Biopharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II study tests a drug called BC006 in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The trial first checks safety in a small group, then randomly assigns patients to receive BC006 or a placebo every two weeks for 24 weeks. The main goal is to see if BC006 improves lung function (measured by FVC) and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BC006 (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment to slow lung scarring and improve breathing in people with idiopathic pulmonary fibrosis.
What could go wrong: This is an early Phase II trial with only 96 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve lung function compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS (IPF)

Contacts and locations

Locations

Dragonboat Biopharmaceutical,Co.,Ltd
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.